Ellis S van Etten1, M Edip Gurol2, Jeroen van der Grond2, Joost Haan2, Anand Viswanathan2, Kristin M Schwab2, Alison M Ayres2, Ale Algra2, Jonathan Rosand2, Mark A van Buchem2, Gisela M Terwindt2, Steven M Greenberg2, Marieke J H Wermer2. 1. From the Departments of Neurology (E.S.v.E., J.H., G.M.T., M.J.H.W.), Radiology (J.v.d.G., M.A.v.B.), and Clinical Epidemiology (A.A.), Leiden University Medical Center; Department of Neurology (J.H.), Alrijne Hospital; Department of Neurology and Neurosurgery (A.A.), Brain Center Rudolf Magnus and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Hemorrhagic Stroke Research Program (M.E.G., A.V., K.M.S., A.M.A., S.M.G.), Department of Neurology, Massachusetts General Hospital Stroke Research Center; and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston. e.s.van_etten@lumc.nl. 2. From the Departments of Neurology (E.S.v.E., J.H., G.M.T., M.J.H.W.), Radiology (J.v.d.G., M.A.v.B.), and Clinical Epidemiology (A.A.), Leiden University Medical Center; Department of Neurology (J.H.), Alrijne Hospital; Department of Neurology and Neurosurgery (A.A.), Brain Center Rudolf Magnus and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands; Hemorrhagic Stroke Research Program (M.E.G., A.V., K.M.S., A.M.A., S.M.G.), Department of Neurology, Massachusetts General Hospital Stroke Research Center; and Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston.
Abstract
OBJECTIVE: To determine whether hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), a monogenetic disease model for the sporadic variant of amyloid angiopathy (sCAA), has a comparable recurrent intracerebral hemorrhage (ICH) risk and mortality after a first symptomatic ICH. METHODS: We included patients with HCHWA-D from the Leiden University Medical Center and patients with sCAA from the Massachusetts General Hospital in a cohort study. Baseline characteristics, hemorrhage recurrence, and short- and long-term mortality were compared. Hazard ratios (HRs) adjusted for age and sex were calculated with Cox regression analyses. RESULTS: We included 58 patients with HCHWA-D and 316 patients with sCAA. Patients with HCHWA-D had fewer cardiovascular risk factors (≥1 risk factor 24% vs 70% in sCAA) and were younger at the time of presenting hemorrhage (mean age 54 vs 72 years in sCAA). Eight patients (14%) with HCHWA-D and 46 patients (15%) with sCAA died before 90 days. During a mean follow-up time of 5 ± 4 years (total 1,550 person-years), the incidence rate of recurrent ICH in patients with HCHWA-D was 20.9 vs 8.9 per 100 person-years in sCAA. Patients with HCHWA-D had a long-term mortality of 8.2 vs 8.4 per 100 person-years in patients with sCAA. After adjustments, patients with HCHWA-D had a higher risk of recurrent ICH (HR 2.8; 95% confidence interval 1.6-4.9; p < 0.001) and a higher long-term mortality (HR 2.8; 95% confidence interval 1.5-5.2; p = 0.001). CONCLUSIONS: Patients with HCHWA-D have worse long-term prognosis after a first ICH than patients with sCAA. The absence of cardiovascular risk factors in most patients with HCHWA-D suggests that vascular amyloid is responsible for the recurrent hemorrhages. HCHWA-D is therefore a pure form of cerebral amyloid angiopathy with an accelerated clinical course and provides a good model to study the pathophysiology and future therapeutic interventions of amyloid-related hemorrhages.
OBJECTIVE: To determine whether hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), a monogenetic disease model for the sporadic variant of amyloid angiopathy (sCAA), has a comparable recurrent intracerebral hemorrhage (ICH) risk and mortality after a first symptomatic ICH. METHODS: We included patients with HCHWA-D from the Leiden University Medical Center and patients with sCAA from the Massachusetts General Hospital in a cohort study. Baseline characteristics, hemorrhage recurrence, and short- and long-term mortality were compared. Hazard ratios (HRs) adjusted for age and sex were calculated with Cox regression analyses. RESULTS: We included 58 patients with HCHWA-D and 316 patients with sCAA. Patients with HCHWA-D had fewer cardiovascular risk factors (≥1 risk factor 24% vs 70% in sCAA) and were younger at the time of presenting hemorrhage (mean age 54 vs 72 years in sCAA). Eight patients (14%) with HCHWA-D and 46 patients (15%) with sCAA died before 90 days. During a mean follow-up time of 5 ± 4 years (total 1,550 person-years), the incidence rate of recurrent ICH in patients with HCHWA-D was 20.9 vs 8.9 per 100 person-years in sCAA. Patients with HCHWA-D had a long-term mortality of 8.2 vs 8.4 per 100 person-years in patients with sCAA. After adjustments, patients with HCHWA-D had a higher risk of recurrent ICH (HR 2.8; 95% confidence interval 1.6-4.9; p < 0.001) and a higher long-term mortality (HR 2.8; 95% confidence interval 1.5-5.2; p = 0.001). CONCLUSIONS: Patients with HCHWA-D have worse long-term prognosis after a first ICH than patients with sCAA. The absence of cardiovascular risk factors in most patients with HCHWA-D suggests that vascular amyloid is responsible for the recurrent hemorrhages. HCHWA-D is therefore a pure form of cerebral amyloid angiopathy with an accelerated clinical course and provides a good model to study the pathophysiology and future therapeutic interventions of amyloid-related hemorrhages.
Authors: E Levy; M D Carman; I J Fernandez-Madrid; M D Power; I Lieberburg; S G van Duinen; G T Bots; W Luyendijk; B Frangione Journal: Science Date: 1990-06-01 Impact factor: 47.728
Authors: Daniel Woo; Laura R Sauerbeck; Brett M Kissela; Jane C Khoury; Jerzy P Szaflarski; James Gebel; Rakesh Shukla; Arthur M Pancioli; Edward C Jauch; Anil G Menon; Ranjan Deka; Janice A Carrozzella; Charles J Moomaw; Robert N Fontaine; Joseph P Broderick Journal: Stroke Date: 2002-05 Impact factor: 7.914
Authors: M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg Journal: Neurology Date: 2006-01-10 Impact factor: 9.910
Authors: C Van Broeckhoven; J Haan; E Bakker; J A Hardy; W Van Hul; A Wehnert; M Vegter-Van der Vlis; R A Roos Journal: Science Date: 1990-06-01 Impact factor: 47.728
Authors: Zahra Shirzadi; Wai-Ying W Yau; Stephanie A Schultz; Aaron P Schultz; Matthew R Scott; Maged Goubran; Parisa Mojiri-Forooshani; Nelly Joseph-Mathurin; Kejal Kantarci; Greg Preboske; Marieke J H Wermer; Clifford Jack; Tammie Benzinger; Kevin Taddei; Hamid R Sohrabi; Reisa A Sperling; Keith A Johnson; Randall J Bateman; Ralph N Martins; Steven M Greenberg; Jasmeer P Chhatwal Journal: Ann Neurol Date: 2022-06-25 Impact factor: 11.274
Authors: Gargi Banerjee; Roxana Carare; Charlotte Cordonnier; Steven M Greenberg; Julie A Schneider; Eric E Smith; Mark van Buchem; Jeroen van der Grond; Marcel M Verbeek; David J Werring Journal: J Neurol Neurosurg Psychiatry Date: 2017-08-26 Impact factor: 10.154
Authors: Nikil Patel; Caroline Banahan; Justyna Janus; Mark A Horsfield; Anthony Cox; Xingfeng Li; Laurie Cappellugola; Jordan Colman; Vincent Egan; Peter Garrard; Emma M L Chung Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: Patryk Kubiszewski; Lansing Sugita; Christina Kourkoulis; Zora DiPucchio; Kristin Schwab; Christopher D Anderson; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Jonathan Rosand; Alessandro Biffi Journal: JAMA Neurol Date: 2020-08-31 Impact factor: 18.302